Bora CDMO Bora CDMO

X
[{"orgOrder":0,"company":"Woodward Pharma Services","sponsor":"GSK","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Woodward Pharma Services LLC Acquires LOVAZA(R) Capsules","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"August 2021","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved"},{"orgOrder":0,"company":"Woodward Pharma Services","sponsor":"Milla Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"A.forall Announces Launch of a Generic Version of Sodium Acetate Injection 4 mEq\/mL","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2024","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved"}]

Find Clinical Drug Pipeline Developments & Deals by Woodward Pharma Services

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            Sodium Acetate-generic Injection 4 mEq/mL is indicated as a source of sodium for addition to large volume intravenous fluids to prevent or correct hyponatremia in patients with restricted or no oral intake.

            Lead Product(s): Sodium Acetate

            Therapeutic Area: Nephrology Product Name: Sodium Acetate-Generic

            Highest Development Status: Approved Product Type: Small molecule

            Recipient: Milla Pharmaceuticals

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 09, 2024

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Woodward Pharma Services LLC, has acquired Lovaza (LO-VEY-ZA) soft gelatin capsules indicated as an adjunct to diet to reduce triglyceride levels in adult patients with severe (greater than or equal to 500 mg/dL) hypertriglyceridemia from GlaxoSmithKline LLC (GSK).

            Lead Product(s): Omega-3-Acid Ethyl Esters 90

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: Lovaza

            Highest Development Status: Approved Product Type: Small molecule

            Recipient: GSK

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Acquisition August 18, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY